Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Drug Discov Today Technol. 2012 Mar 29;10(1):e121–e128. doi: 10.1016/j.ddtec.2012.02.003

Figure 3. Yeast α-synuclein model as a small molecule screening platform.

Figure 3

(A) Three yeast strains expressing increasing amounts of α-syn-GFP exhibit a dose-dependent increase in intracellular foci formation and loss of plasma membrane localization. (B) The same three yeast strains exhibit an increase in toxicity with increase α-syn dose. (C) Basic protein homeostasis machinery is conserved between yeast and man, allowing yeast-based screening to provide insights into human disease.